CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (Globe NEWSWIRE) — Acumen Prescription drugs, Inc. (NASDAQ: ABOS), a scientific phase biopharmaceutical company focused on the development of novel qualified therapeutics for Alzheimer’s ailment (Advert), nowadays declared that the firm will report its monetary success for the fourth quarter and total 12 months 2021 on Monday, March 28, 2022. The corporation will host a meeting connect with and live audio webcast at 4:30 p.m. ET to present a enterprise and money update.
Acumen will host a conference connect with and are living audio webcast on Monday, March 28, at 4:30 pm ET. The are living webcast may well be accessed from the Traders part of the Company’s web page at www.acumenpharm.com. Please link to the web page prior to the begin of the meeting simply call to assure ample time for any program downloads that may well be vital. Investors could take part in the convention call by dialing +1 877 311-0573 in the U.S., or +1 470 495-9505 outdoors the U.S., and moving into passcode 3629669.
An archived version of the webcast will be offered for at the very least 30 days in the Traders section of the Firm’s site at www.acumenpharm.com.
About Acumen Prescribed drugs, Inc.
Acumen, headquartered in Charlottesville, VA, with clinical operations dependent in Carmel, IN, is a clinical stage biopharmaceutical firm developing a novel disorder-modifying strategy to treat Alzheimer’s ailment. Acumen’s scientific founders pioneered investigate on AβOs, which a developing body of proof signifies are most important triggers of Alzheimer’s disorder pathology. Acumen is at this time centered on advancing its investigational immunotherapy drug, ACU193, a humanized monoclonal antibody that selectively targets poisonous AβOs in INTERCEPT-Advertisement, a Section I clinical trial involving early Alzheimer’s ailment sufferers. For additional details, take a look at www.acumenpharm.com.